Development of a Cancer Vaccine Using In Vivo Click‐Chemistry‐Mediated Active Lymph Node Accumulation for Improved Immunotherapy

• DOI: 10.1002/adma.202006007
• Publication Date: 2021-04-01T05:48:19Z
• Authors: Hao Qin; Ruifang Zhao; Yuting Qin; Jin Zhu; Long Chen; Chunzhi Di; Xuexiang Han; Keman Cheng; Yinlong Zhang; Ying Zhao; Jian Shi; Gregory J. Anderson; Yuliang Zhao; Guangjun Nie
• Keywords: Cancer vaccine; Cancer Immunotherapy

Abstract Due to their ability elicit a potent immune reaction with low systemic toxicity, cancer vaccines represent promising strategy for treating tumors. Considerable effort has been directed toward improving the in vivo efficacy of vaccines, direct lymph node (LN) targeting being most approach. Here, click‐chemistry‐based active LN accumulation system (ALAS) is developed by surface modification lymphatic endothelial cells an azide group, which provide targets dibenzocyclooctyne (DBCO)‐modified liposomes, improve delivery encapsulated antigen and adjuvant LNs. When loading OVA 257–264 peptide poly(I:C), formulation elicits enhanced CD8 + T cell response vivo, resulting much more efficient therapeutic effect prolonged median survival mice. Compared treatment DBCO‐conjugated liposomes (DL)‐Ag/Ad without targeting, percent ALAS‐vaccine‐treated mice improves 100% over 60 days. Altogether, findings indicate that novel ALAS approach powerful deliver vaccine components LNs antitumor immunity.